Search

Search Constraints

You searched for: Author/Creator Sergon, M.

Search Results

2. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (18th August 2021)

3. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (1st December 2021)